Overview

Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Status:
Active, not recruiting
Trial end date:
2026-06-30
Target enrollment:
0
Participant gender:
Female
Summary
To evaluate the efficacy, safety and tolerability of maintenance therapy with BGB-290(Pamiparib) versus placebo in Chinese participants with recurrent ovarian cancer who achieved a complete response (CR) or partial response (PR) after platinum-based chemotherapy
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
BeiGene
Criteria
Key Inclusion Criteria:

1. Histologically diagnosed high-grade serous or endometrioid ovarian cancer (including
primary peritoneal and fallopian tube cancer)

2. Completion of ≥2 previous platinum-containing regimens (eg, carboplatin or cisplatin)

3. Complete response (CR) or partial response (PR) achieved with last platinum-based
chemotherapy regimen as determined by investigator per Response Evaluation Criteria in
Solid Tumors (RECIST) Version 1.1

4. Ability to be randomized ≤8 weeks after last dose of platinum

Key Exclusion Criteria:

1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor

2. Progressive disease (PD) as per CA-125 criteria before randomization

3. Diagnosis of myelodysplastic syndrome (MDS)

4. Known history of intolerance to the excipients of the Pamiparib capsule

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.